Myovant Sciences (Myovant Sciences) Inventory-to-Revenue : 0.27 (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Myovant Sciences Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Myovant Sciences's Average Total Inventories for the quarter that ended in Dec. 2022 was $26.6 Mil. Myovant Sciences's Revenue for the three months ended in Dec. 2022 was $100.2 Mil. Myovant Sciences's Inventory-to-Revenue for the quarter that ended in Dec. 2022 was 0.27.

Myovant Sciences's Inventory-to-Revenue for the quarter that ended in Dec. 2022 increased from Sep. 2022 (0.21) to Sep. 2022 (0.27)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Myovant Sciences's Days Inventory for the three months ended in Dec. 2022 was 70.83.

Inventory Turnover measures how fast the company turns over its inventory within a year. Myovant Sciences's Inventory Turnover for the quarter that ended in Dec. 2022 was 1.29.

Myovant Sciences Inventory-to-Revenue Historical Data

The historical data trend for Myovant Sciences's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myovant Sciences Inventory-to-Revenue Chart

Myovant Sciences Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Inventory-to-Revenue

Get a 7-Day Free Trial

0.04

0.02

Myovant Sciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Inventory-to-Revenue	Get a 7-Day Free Trial															0.12	0.12	0.12	0.21	0.27

Competitive Comparison of Myovant Sciences's Inventory-to-Revenue

For the Biotechnology subindustry, Myovant Sciences's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myovant Sciences's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Inventory-to-Revenue falls into.

Myovant Sciences Inventory-to-Revenue Calculation

Myovant Sciences's Inventory-to-Revenue for the fiscal year that ended in Mar. 2022 is calculated as

	Inventory-to-Revenue (A: Mar. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Mar. 2021 )	+	Total Inventories (A: Mar. 2022 ))	/	count )	/	Revenue (A: Mar. 2022 )
=	( (2.611	+	7.584)	/	2 )	/	230.972
=	5.0975					/	230.972
=	0.02

Myovant Sciences's Inventory-to-Revenue for the quarter that ended in Dec. 2022 is calculated as

	Inventory-to-Revenue (Q: Dec. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2022 )	+	Total Inventories (Q: Dec. 2022 ))	/	count )	/	Revenue (Q: Dec. 2022 )
=	( (23.047	+	30.084)	/	2 )	/	100.229
=	26.5655					/	100.229
=	0.27

Myovant Sciences (NYSE:MYOV) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Myovant Sciences's Days Inventory for the three months ended in Dec. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2022 )	/	Cost of Goods Sold (Q: Dec. 2022 )	*	Days in Period
	=	26.5655	/	34.226	*	365 / 4
	=	70.83

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Myovant Sciences's Inventory Turnover for the quarter that ended in Dec. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2022 )	/	Average Total Inventories (Q: Dec. 2022 )
	=	34.226	/	26.5655
	=	1.29

Myovant Sciences Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Myovant Sciences (Myovant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Myovant Sciences Ltd (NYSE:MYOV) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB

Website

https://www.myovant.com

Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Executives

Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Lauren Merendino	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David C Marek	director, officer: Principal Executive Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Matthew Lang	officer: General Counsel & Corp. Secy.	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Ferreira Juan Camilo Arjona	officer: Chief Medical Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Uneek Mehra	officer: Principal Financial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Shigeyuki Nishinaka	director	5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Nancy Valente	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Frank Karbe	officer: Principal Fin'l & Accounting	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Kim Sablich	officer: Chief Commercial Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Hiroshi Nomura	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
Sumitovant Biopharma Ltd.	10 percent owner	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd	10 percent owner	6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Adele M. Gulfo	director	ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957